Nancy Lin, MD, explores the role of CDK4/6 inhibitors in metastatic breast cancer management

A New Treatment for Breast Cancer Patients with Brain Metastases: An Interview with Dr. Nancy LinПодробнее

The use of frontline CDK4/6 inhibitors + endocrine therapy in metastatic breast cancerПодробнее

Sequencing first-line CDK4/6 inhibitors in metastatic breast cancerПодробнее

Nancy Lin, MD, on breast cancer treatment | Dana-Farber Cancer InstituteПодробнее

CDK4/6 Inhibitors in Metastatic Breast CancerПодробнее

CDK4/6 Inhibitors in HR+ Metastatic Breast CancerПодробнее

CDK4/6 Inhibition’s Role in HR+ Metastatic Breast CancerПодробнее

Overcoming resistance to CDK4/6 inhibitors in ER+ breast cancer via ctDNAПодробнее

Erika Hamilton, MD, on how CDK4/6 inhibitors transformed the management of metastatic breast cancerПодробнее

The Latest Research and Clinical Trials for ER+ and Triple-Negative Metastatic Breast CancerПодробнее

Interactive Case: Choosing and Using CDK4/6 Inhibitors in Breast Cancer - Second-line TherapyПодробнее

Study of Palbociclib after CDK & Endocrine Therapy in ER+/HER2- Metastatic Breast CancerПодробнее

CDK4/6 Inhibitors in Metastatic Breast CancerПодробнее

Metastatic Breast Cancer: CDK4/6 InhibitorsПодробнее

Clinical Experience: CDK4/6 Inhibitors in Breast CancerПодробнее

CDK4/6 Inhibitors in HER2-Negative Breast Cancer Based on Phase III MONALEESA-7 TrialПодробнее

Metastatic Breast Cancer: CDK4/6 InhibitorsПодробнее

CDK 4/6 Inhibitors in Metastatic Breast CancerПодробнее

CDK 4/6 Inhibitors: How are they used in metastatic breast cancer treatment?Подробнее